Skip to main content
Biomed Europa

Biomed Europa: A challenge to the pharmaceutical oligopoly

Dana Brown

Dana Brown

Director of the Next System Project more

Health & Wellbeing Democratic Ownership

In his new white paper, “Biomed Europa: after the coronavirus, a public infrastructure to overcome the pharmaceutical oligopoly,” Italian economist Massimo Florio proposes an international, transparent, public pharmaceutical and biomedical institute for Europe that would focus its efforts on the areas of greatest human and social impact. 

Recognizing that “the COVID-19 pandemic has exposed profound weaknesses in a global health system that in the last decades relied…too heavily on the pro-profit private sector for the discovery, development and distribution of new drugs,” Florio proposes Biomed Europa as a way to break Big Pharma’s monopoly on Europe’s medicine supply and assure the public interest is prioritized in medical innovation in the future. 

The model Florio lays out would represent both large-scale international research infrastructure—akin to that of the European Organization for Nuclear Research—as well as a knowledge-intensive public enterprise with an industrial policy mission, similar to that of the European Space Agency. Biomed Europa would be designed to overcome the weaknesses of the current pharmaceutical market, where research priorities are distorted by the profit motive, and would function across the supply chain in order to assure that public-interest drug development and production is successful. 

Similar to the model we at The Democracy Collaborative have developed for the U.S. pharmaceutical sector, Professor Florio suggests Biomed Europa manage its intellectual property in the public interest. The proposed project could become the largest public biomedical institute in the world and the largest single enterprise in the sector, providing an important counterbalance to the political power of Big Pharma. Most importantly, the social benefits of long-term and large-scale public international drug development and production would come from lessened economic effects of severe pathologies, improved quality of life, and social cohesion. 

» Read the full proposal here

Dana Brown

Dana Brown

Director of the Next System Project more

More related work

All health is public health

All health is public health: Busting the myths of choice and commodity

For decades, we have been sold a myth of private health. It is a myth that our health is largely a product of individual choices and personal responsibilities. It is a myth that our healthcare is a service that private corporations can provide, and for which we must pay to survive. read more
COVID-19 and 21st century public ownership

COVID-19 and 21st century public ownership

COVID-19 has made the case for reimagining the ownership and governance of our economies on both sides of the Atlantic more urgent than ever. To meet the needs of the moment, an agenda to extend democratic public ownership is essential. read more
Los elementos de una economía democrática

Los elementos de una economía democrática

Las políticas y prácticas tradicionales evidentemente nos están fallando frente a las tendencias decadentes de largo plazo en cuanto a la desigualdad de ingresos, la concentración de la riqueza, la desinversión y desplazamiento de las comunidades, la pobreza persistente con carácter racial y geog read more